BIO, BIO-B · CIK 0000012208 · operating
Bio-Rad Laboratories develops, manufactures, and distributes life science research and clinical diagnostic products globally. The company operates through two primary segments: Life Science and Clinical Diagnostics. The Life Science segment produces instruments, reagents, and consumables used to separate, purify, characterize, and quantify biological materials including cells, proteins, and nucleic acids. These products serve universities, research institutions, pharmaceutical manufacturers, biotechnology companies, and food producers for applications spanning basic research, biopharmaceutical manufacturing, quality control, and food safety testing. The Clinical Diagnostics segment designs and manufactures diagnostic test systems, informatics software, and quality control products for clinical laboratories, hospitals, transfusion facilities, and physician offices.
The company distributes its products through a direct commercial organization as well as an indirect network of distributors, agents, and resellers across the United States, Europe, Asia, Canada, Latin America, and other international markets. Bio-Rad operates with approximately 7,450 full-time employees and maintains headquarters in Hercules, California. The company was founded in 1952.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $27.85 | $27.87 | +208.9% | |
| 2024 | $-25.57 | $-25.57 | -310.6% | |
| 2023 | $12.14 | $12.15 | -56.3% | |
| 2022 | $27.78 | $27.89 | +152.8% | |
| 2021 | $-52.59 | $-52.59 | -289.1% | |
| 2020 | $27.81 | $28.13 | +51.9% | |
| 2019 | $18.31 | $18.50 | +166.0% | |
| 2018 | $-27.73 | $-27.73 | -1108.4% | |
| 2017 | $2.75 | $2.78 | +492.9% | |
| 2016 | $-0.70 | $-0.70 | -141.7% | |
| 2015 | $1.68 | $1.69 | +25.4% | |
| 2014 | $1.34 | $1.35 | -50.2% | |
| 2013 | $2.69 | $2.72 | +84.2% | |
| 2012 | $1.46 | $1.48 | -29.8% | |
| 2011 | $2.08 | $2.11 | -68.4% | |
| 2010 | $6.59 | $6.70 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-13 | 0000012208-26-000010 | SEC ↗ |
| 2024-12-31 | 2025-02-14 | 0000012208-25-000007 | SEC ↗ |
| 2023-12-31 | 2024-02-16 | 0000012208-24-000013 | SEC ↗ |
| 2022-12-31 | 2023-02-17 | 0000012208-23-000031 | SEC ↗ |
| 2021-12-31 | 2022-02-11 | 0000012208-22-000011 | SEC ↗ |
| 2020-12-31 | 2021-02-16 | 0000012208-21-000012 | SEC ↗ |
| 2019-12-31 | 2020-03-02 | 0000012208-20-000012 | SEC ↗ |
| 2018-12-31 | 2019-04-01 | 0000012208-19-000014 | SEC ↗ |
| 2017-12-31 | 2018-04-16 | 0000012208-18-000014 | SEC ↗ |
| 2016-12-31 | 2017-03-01 | 0000012208-17-000012 | SEC ↗ |
| 2015-12-31 | 2016-02-29 | 0000012208-16-000053 | SEC ↗ |
| 2014-12-31 | 2015-03-02 | 0000012208-15-000012 | SEC ↗ |
| 2013-12-31 | 2014-03-18 | 0000012208-14-000020 | SEC ↗ |
| 2012-12-31 | 2013-03-18 | 0000012208-13-000007 | SEC ↗ |
| 2011-12-31 | 2012-02-29 | 0000012208-12-000008 | SEC ↗ |